Key result
Gut microbiota dysbiosis and metabolites like TMAO contribute to cardiovascular diseases, whereas short-chain fatty acids and a balanced microbiota offer protection.
Why the study?
To understand the bidirectional relationship between the gut microbiota and CVDs, and how microbial dysbiosis contributes to atherosclerosis, hypertension, and heart failure.
This comprehensive review highlights the critical bidirectional relationship between gut microbiota and cardiovascular health, emphasizing the therapeutic potential of targeting the microbiome.
Should not yet change clinical practice; extends observational links but leaves causal therapeutic roles open for RCTs.
This review examines the bidirectional relationship between the gut microbiota and cardiovascular diseases (CVDs), aiming to understand how microbial dysbiosis contributes to CVDs, including atherosclerosis, hypertension, and heart failure. Recent research emphasizes the gut microbiota’s role in modulating immunity via SCFAs and tryptophan metabolites, maintaining intestinal barrier integrity, and producing metabolites such as SCFAs (acetate, propionate, butyrate) and pro‐atherogenic TMAO. Dietary patterns, particularly the Mediterranean versus Western diet, significantly influence gut microbiota composition and CVD risk. Polyphenols and exercise have shown positive effects on gut microbiota and cardiovascular outcomes. A significant interplay exists between gut microbiota and cardiovascular health. Dysbiosis and metabolites like TMAO and LPS are implicated in CVD, while SCFAs and a balanced microbiota offer protection. Future research should focus on precision medicine, next‐gen probiotics, optimized FMT, and multiomics approaches to identify personalized CVD therapies.
No takes yet. Share an insight, caveat, or question.
Mylavarapu et al. (2026) conducted a review in Cardiovascular diseases. Gut microbiota modulation was evaluated. Gut microbiota dysbiosis and metabolites like TMAO contribute to cardiovascular diseases, whereas short-chain fatty acids and a balanced microbiota offer protection.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: